Tuberculosis preventive treatment uptake among patients initiating antiretroviral therapy in Malawi: Children left behind
Open Access
- 1 January 2025
- journal article
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1)
Abstract
Background: Tuberculosis preventive treatment (TPT) is recommended for people living with HIV (PLHIV) to reduce the tuberculosis (TB) incidence in regions with a high prevalence of TB. We evaluated the uptake and completion of TPT among newly initiated antiretroviral therapy (ART) patients in a programme setting in Malawi. Objectives: To describe TPT initiation and completion rates, and explore factors associated with TPT initiation and completion among newly initiated ART patients. Method: We conducted a retrospective cohort study analysing routinely collected data from 10 ART facilities. We included all patients who initiated ART between January 2023 and March 2023, with follow-up for 12 months. We used descriptive statistics to summarise demographic and clinical characteristics, and logistic regression to assess factors associated with TPT initiation and completion. Results: A total of 1289 patients were enrolled; 1015 (78.7%) were eligible for TPT. Of these, 820 (80.8%) initiated TPT; 610 (74.4%) completed treatment. Children (< 10 years), adolescents (10–19 years), patients presenting with WHO HIV clinical stage three or four conditions, and urban residents were less likely to initiate TPT: adjusted odds ratio (aOR) 0.12 (95% confidence interval [CI] 0.06–0.22), aOR 0.30 (95% CI 0.15–0.59), aOR 0.35 (95% CI 0.21–0.60), and aOR 0.56 (95% CI 0.34–0.90), respectively. Patients who received daily isoniazid for 6 months had reduced odds of completing TPT (aOR 0.22; 95% CI 0.11–0.42) compared with weekly isoniazid plus rifapentine for 3 months. Conclusion: High TPT initiation and completion rates were observed among eligible patients initiating ART in Malawi. However, children lag in TPT initiation. Targeted interventions that improve TPT uptake among paediatric patients are required.Keywords
This publication has 28 references indexed in Scilit:
- Child-friendly rifapentine formulation is a game changerThe Lancet Infectious Diseases, 2024
- Factors associated with HIV viral suppression among children and adults receiving antiretroviral therapy in Malawi in 2021: Evidence from the Laboratory Management Information SystemTropical Medicine & International Health, 2022
- Paediatric tuberculosis – new advances to close persistent gapsInternational Journal of Infectious Diseases, 2021
- Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIVAIDS, 2020
- The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale‐up in MalawiJournal of the International AIDS Society, 2019
- Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden SettingsClinical Infectious Diseases, 2018
- High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis InfectionClinical Infectious Diseases, 2017
- Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settingsAIDS, 2015
- A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in AfricaNew England Journal of Medicine, 2015
- Tuberculosis in ChildrenClinics in Chest Medicine, 2005